DiaMedica Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- DiaMedica completed enrollment in the first 2 cohorts of its investigator-sponsored Phase 2 early onset fetal growth restriction study: 12 participants, with 6 treated at 5 micrograms per kg and 6 at 10 micrograms per kg.
- In October, Remedy 2 enrolled its 200th participant, reaching the prespecified threshold for the interim analysis; the trial’s primary efficacy endpoint is the proportion of participants with a Modified Rankin Scale score of 0 to 1 at day 90.
- As of September 30th, 2026, cash, cash equivalents, and short-term investments were $34.9 million, compared with $59.9 million at December 31st, 2025; working capital was $28 million.
- Net cash used in operating activities for the first 9 months of 2026 was $26 million, compared with $21.3 million for the first 9 months of 2025.
- Research and development expense was $9.2 million for the 3rd quarter and $25.4 million for the first 9 months of 2026, compared with $6.4 million and $17.9 million for the corresponding periods of 2025.
- General and administrative expense was $2.4 million for the 3rd quarter and $7.2 million for the first 9 months of 2026, compared with $2.6 million and $7.3 million for the same periods in 2025.
- Net loss for the 3rd quarter was $11.3 million, or $0.21 per share, compared with $8.6 million, or $0.17 per share, in the 3rd quarter of 2025; net loss for the 9 months ended September 30th was $31.5 million, or $0.58 per share, compared with $24 million, or $0.53 per share, in the prior-year period.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to DiaMedica Therapeutics Third Quarter 2026 Earnings Conference Call. An audio recording of today's webcast will be available following the call on DiaMedica's website, diamedica.com, in the Investor Relations section. Before we begin, please note that management will be making forward-looking statements. These statements are subject to risks and uncertainty that could cause actual results to differ materially from those expressed or implied. Additional information about these risks appears in the cautionary statement in the company's earnings press release issued yesterday and in DiaMedica's filings with the Securities and Exchange Commission, including its most recent Form 10-K and Form 10-Q. Statements on this call speak only as of today, November 13th, 2026. Following prepared remarks, we will open the call for questions. I would now like to introduce Rick Pauls, DiaMedica's President and Chief Executive Officer.
Rick, please go ahead. Thank you, operator, and good morning, everyone.
Thank you for joining our third quarter earnings call. With me today are Dr. Julie Krop, our Chief Medical Officer, and Scott Kellen, our Chief Financial Officer. Since our last earnings call, we achieved two major clinical milestones. First, enrollment was completed in the first two cohorts of the investigator-sponsored phase II early-onset fetal growth restriction study. Second, in October, we enrolled the 200th participant in ReMEDy2, our pivotal phase II/III trial in acute ischemic stroke. With this, we attained the pre-specified enrollment threshold required for the ReMEDy2 interim analysis. Together, these milestones bring us closer to important clinical readouts that could help define the next stage of development for DM199 in fetal growth restriction, preeclampsia, and acute ischemic stroke.
We also continue to prepare for additional studies in preeclampsia, including our company-sponsored phase II trial, and made progress addressing FDA feedback on the non-clinical package needed for a U.S. Investigational New Drug application for preeclampsia. I will walk through the major updates. Julie will discuss the clinical objectives in more detail, and Scott will review our financial results. As a reminder, DM199, generic name rinvecalinase alfa, is a recombinant form of human tissue kallikrein one, or KLK1. Through activation of the bradykinin two receptor pathway, we believe DM199 has the potential to improve vascular health and function, ultimately improving blood flow. This is a completely novel mechanism of action and provides a common therapeutic rationale across preeclampsia, fetal growth restriction, acute ischemic stroke, and other diseases, even though the clinical objectives and endpoints differ across these indications. Let me begin with early-onset fetal growth restriction program, or FGR.
Professor Cluver has now completed enrollment in the first two cohorts of the phase II study being conducted at Tygerberg Hospital in Cape Town, South Africa. Together, these cohorts include 12 participants, with six treated at five micrograms per kg and six treated at 10 micrograms per kg. This is the first clinical evaluation of DM199 in women with early-onset fetal growth restriction. Early-onset FGR is a pregnancy disorder associated with significant risks to the fetus, frequently resulting from placental insufficiency, creating impaired blood flow that restricts the supply of oxygen and nutrients to the baby. Currently, no therapy is approved to treat FGR. The only option today for physicians is to closely monitor both mother and baby, balancing the risk of stillbirth and fetal complications from worsening placental insufficiency against the serious neonatal risks of delivering babies prematurely.
In pregnancies complicated by preeclampsia, maternal risk also includes severe hypertension and organ injury. The current early-onset FGR study is evaluating repeated subcutaneous dosing of DM199, with the objective of assessing whether DM199 can safely prolong pregnancy while minimizing risk to the mother and baby. Assessments include maternal and fetal safety, measures of uteroplacental vascular resistance, birth weight percentile, and duration of pregnancy. The dose for the third cohort will be selected based on the findings from the first two cohorts. on Tuesday, November 24th, at 8:00 A.M. Eastern Time, we will host a virtual key opinion leader event focusing on fetal growth restriction, featuring preliminary results from both completed cohorts. Professor Cluver will be joined by Professor Stephen Tong and Professor Susan Walker, both from The University of Melbourne, and Professor Andrew Shennan from King's College London.
The panel will discuss the treatment landscape and unmet need, the clinical rationale for DM199, and preliminary safety and clinical observations in the context of current maternal fetal medicine best practices. Within the investigator-sponsored trial, two additional preeclampsia studies are expected to begin enrollment by the end of 2026. One comprises up to 30 women with early-onset preeclampsia receiving repeated subcutaneous dosing of DM199 until delivery. This is referred to as our part two of the study. The second study will include up to 30 women with late-onset or late-stage preeclampsia who are acutely hypertensive with delivery expected within 72 hours, referred to as part 1B. In the second study, patients will receive DM199 via continuous intravenous infusion, which may provide insight into whether IV dosing of DM199 can help control severe hypertension. We believe every day matters for mom and baby.
Switching to IV DM199 may enable further prolongation of pregnancy for these women beyond subcutaneous dosing. We are also advancing our company-sponsored phase II program in early-onset preeclampsia. Health Canada authorized a protocol amendment to the open-label phase II dose-finding study in September, and preparations continue to initiate enrollment at Canadian sites. We also plan to expand the study into the U.K., subject to regulatory authorization. In October, the study received conditional authorization from the European Medicines Agency, or EMA, with consideration for full approval after country-specific ethical and site requirements, creating an opportunity for future European expansion. This trial is designed to evaluate approximately 30 patients with early-onset preeclampsia across three dose levels, drawing on the part 1A preeclampsia experience and emerging FGR observations.
Together, both of these studies will provide further information on dosing and pharmacologic activity in different clinical settings, allowing us to develop the dosing plan for use in larger preeclampsia trials. In the U.S., our focus remains on addressing FDA's feedback regarding the non-clinical reproductive toxicology data to support an Investigational New Drug application, or IND, to study DM199 in preeclampsia in the U.S. Last quarter, we discussed FDA feedback indicating that our completed rat reproductive toxicology studies may be acceptable to support an IND application. FDA's acceptance would depend on our ability to demonstrate that DM199 exposure and enzymatic activity were maintained at adequate levels throughout those studies, and that DM199 produces a sufficient pharmacologic effect in rats to justify their use as a toxicology species. We initiated an additional rat study during the third quarter to generate this data.
I'm pleased to report that the in-life portion of the study has been complete, and DM199 was well tolerated by the animals. We expect the pharmacokinetic and pharmacologic results in the coming weeks, and once the report is complete, we plan to submit to the FDA. Our other major recent clinical milestone was in acute ischemic stroke, where ReMEDy2 reached the enrollment threshold for its pre-specified interim analysis. Acute ischemic stroke, when a blood clot blocks blood flow to the brain, can cause profound lasting disability or death. Current reperfusion treatments, including thrombolytic drugs, which attempt to dissolve the clot, and mechanical thrombectomy, which attempts to physically remove the clot, can be highly effective for certain eligible patients, but their use is limited by clinical eligibility, treatment time window, and the location of the clot. Most stroke patients either cannot receive these treatments or still experience significant disability despite treatment.
This is why stroke also remains a significant unmet medical need, and additional approaches to preserve at-risk brain tissue and improve function recovery are urgently needed. Following the required 90-day follow-up of the 200th participant, the Independent Data Safety Monitoring Board, or DSMB, will examine the primary efficacy endpoint, the proportion of participants with a modified Rankin Scale score of 0 to one at day 90, indicating an excellent functional outcome. As part of the trial's pre-specified adaptive design, the DSMB will use this efficacy data to determine whether the study should continue, and if so, whether the final sample size should be adjusted. If the trial continues, the final enrollment target will range from 300 to 728 participants under the pre-specified statistical plan. DiaMedica will remain blinded to the treatment effect data reviewed by the DSMB.
If successful, ReMEDy2 has the potential to serve as a pivotal trial supporting a future New Drug Application, or NDA, for use of DM199 in acute ischemic stroke. Patient recruitment continues during the completion of the follow-up period and data preparations for interim review. We expect the DSMB to complete its analysis in the first quarter of 2027. With that, I will turn the call over to Julie to discuss the clinical programs in more detail.
Julie? Thank you, Rick, and good morning, everyone.
I would like to expand on two aspects of our pregnancy-related development strategy. First, what are we seeking to learn from the FGR cohorts? And second, how the initial preeclampsia findings are informing the next studies. Severe early-onset fetal growth restriction presents a substantial challenge because impaired placental function can severely limit the fetus's ability to grow and develop. As Rick noted, clinical management requires balancing the potential benefit of prolonging gestation against the maternal and fetal risks of continuing the pregnancy. We are evaluating whether and to what degree DM199 can favorably affect vascular physiology to improve vascular health and blood flow, and ultimately support improved outcomes for both the mother and the baby. The ongoing phase II FGR IST trial is evaluating repeated subcutaneous dosing of DM199 in women with early-onset disease.
Key assessments include safety and tolerability and umbilical artery Doppler indices that reflect the degree of resistance to blood flow from the fetus to the placenta. Abnormal Doppler findings, particularly absent or reversed end-diastolic flow, help guide the timing of delivery in pregnancies complicated by fetal growth restriction. Changes in these physiologic parameters will provide important information about the pharmacologic activity of DM199 and help inform further development. At the November 24th KOL event, we will review preliminary observations from the two six-participant cohorts tested at DM199 subcutaneous dose levels five and 10 micrograms per kilogram, respectively. Although this is an early open-label study involving a small number of patients, the findings will provide an initial opportunity to assess DM199 safety, pharmacologic activity, and potential clinical effects in women with early-onset FGR.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
